CA2468344A1 - Methods and compositions for treating lesions of the respiratory epithelium - Google Patents

Methods and compositions for treating lesions of the respiratory epithelium Download PDF

Info

Publication number
CA2468344A1
CA2468344A1 CA002468344A CA2468344A CA2468344A1 CA 2468344 A1 CA2468344 A1 CA 2468344A1 CA 002468344 A CA002468344 A CA 002468344A CA 2468344 A CA2468344 A CA 2468344A CA 2468344 A1 CA2468344 A1 CA 2468344A1
Authority
CA
Canada
Prior art keywords
composition
seq
trefoil
trefoil peptide
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002468344A
Other languages
English (en)
French (fr)
Inventor
Daniel K. Podolsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2468344A1 publication Critical patent/CA2468344A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002468344A 2001-11-28 2002-11-27 Methods and compositions for treating lesions of the respiratory epithelium Abandoned CA2468344A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33383601P 2001-11-28 2001-11-28
US60/333,836 2001-11-28
PCT/US2002/038258 WO2003045332A2 (en) 2001-11-28 2002-11-27 Methods and compositions for treating lesions of the respiratory epithelium

Publications (1)

Publication Number Publication Date
CA2468344A1 true CA2468344A1 (en) 2003-06-05

Family

ID=23304463

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002468344A Abandoned CA2468344A1 (en) 2001-11-28 2002-11-27 Methods and compositions for treating lesions of the respiratory epithelium

Country Status (8)

Country Link
US (2) US20030114384A1 (enExample)
EP (1) EP1461076A4 (enExample)
JP (1) JP2005532988A (enExample)
CN (1) CN1617739A (enExample)
AU (1) AU2002351181B2 (enExample)
CA (1) CA2468344A1 (enExample)
MX (1) MXPA04005053A (enExample)
WO (1) WO2003045332A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525018B1 (en) * 1999-05-17 2003-02-25 The General Hospital Corp. Treating eye disorders using intestinal trefoil proteins
US20030185838A1 (en) * 2001-11-28 2003-10-02 Podolsky Daniel K. Methods and compositions for treating lesions of the respiratory epithelium
US20030186882A1 (en) * 2001-07-31 2003-10-02 Podolsky Daniel K. Methods and compositions for treating and preventing distal bowel lesions
US7654998B1 (en) 1999-08-23 2010-02-02 Aeris Therapeutics, Inc. Tissue volume reduction
US6610043B1 (en) 1999-08-23 2003-08-26 Bistech, Inc. Tissue volume reduction
US20030105016A1 (en) * 2001-09-06 2003-06-05 Podolsky Daniel K. Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions
US20040171544A1 (en) * 2001-04-24 2004-09-02 Barker Nicholas P. Trefoil domain-containing polypeptides and uses thereof
US20030148949A1 (en) * 2001-10-05 2003-08-07 Podolsky Daniel K. Methods and compositions for treating dermal lesions
US20060189526A1 (en) * 2002-04-24 2006-08-24 Podolsky Daniel K Compositions containing an intestinal trefoil peptide and a mucoadhesive
US7538082B2 (en) 2001-04-24 2009-05-26 The General Hospital Corporation Methods and compositions for treating oral and esophageal lesions
US20030181384A1 (en) * 2001-09-06 2003-09-25 Podolsky Daniel K. Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions
US20030185839A1 (en) * 2001-10-05 2003-10-02 Podolsky Daniel K. Methods and compositions for treating dermal lesions
US20030181356A1 (en) * 2002-03-11 2003-09-25 Edward Ingenito Compositions and methods for treating emphysema
EP1494530A4 (en) * 2002-03-26 2009-06-24 Gen Hospital Corp COMBINATION THERAPY USING TREFLE LEAF PEPTIDES
US20060188471A1 (en) * 2002-10-31 2006-08-24 Podolsky Daniel K Methods of treating epithelial lesions
AU2004206868A1 (en) * 2003-01-17 2004-08-05 Children's Hospital Medical Center Use of TFF2, or agents inducing TFF2, in the therapy of allergies
CA2562009A1 (en) * 2004-04-05 2005-10-20 Sepracor Inc. (r,r)-formoterol in combination with other pharmacological agents
US8075771B2 (en) * 2005-02-17 2011-12-13 E. I. Du Pont De Nemours And Company Apparatus for magnetic field gradient enhanced centrifugation
WO2008073627A2 (en) * 2006-11-03 2008-06-19 Alba Therapeutics Corporation Method of diagnosing and treating asthma
CA2678455C (en) 2007-01-10 2019-02-12 Board Of Regents The University Of Texas System Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery
WO2009006246A1 (en) * 2007-06-29 2009-01-08 Alea Therapeutics Corp. Use of tight junction antagonists in the treatment of acute long injury and acute respiratory distress syndrome
WO2010014552A1 (en) * 2008-08-01 2010-02-04 Alpha Synergy Development, Inc. Vasoconstriction compositions and methods of use
US20130274171A1 (en) * 2010-06-04 2013-10-17 Trifoilium Aps Trefoil factors (tff) for the treatment of chronic pulmonary diseases
CN105582526B (zh) * 2016-02-25 2020-07-17 山东睿鹰制药集团有限公司 三叶因子2在制备治疗及预防肺/支气管急性炎症疾病药物方面的应用
US20230173028A1 (en) * 2020-03-30 2023-06-08 Shandong Ruiying Pioneer Pharmaceutical Co., Ltd Application of TFF2 Protein and IFN-k Protein Combination in Treatment of a Novel Coronavirus Infection

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
US4370317A (en) * 1980-09-10 1983-01-25 Novo Industri A/S Pancreatic spasmolytic polypeptide
US6063755A (en) * 1991-02-14 2000-05-16 The General Hospital Corporation Intestinal trefoil proteins
US6221840B1 (en) * 1991-02-14 2001-04-24 The General Hospital Corporation Intestinal trefoil proteins
CA2104104A1 (en) * 1991-02-14 1992-09-03 Daniel K. Podolsky Intestinal trefoil proteins
DK6893D0 (da) * 1993-01-21 1993-01-21 Novo Nordisk As Peptid
US5563046A (en) * 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US6426404B1 (en) * 1997-08-25 2002-07-30 The General Hospital Corporation Receptor for intestinal trefoil factor
HUP0103160A3 (en) * 1998-08-26 2002-11-28 Smithkline Beecham Corp Pharmaceutical compositions for treating pulmonary diseases containing pde4 inhibitor
US6372439B2 (en) * 1998-10-01 2002-04-16 James R. Goldenring Screen for gastric adenocarcinoma
AU2590201A (en) * 1999-12-23 2001-07-03 Human Genome Sciences, Inc. Trefoil domain-containing polynucleotides, polypeptides, and antibodies
EP1341817A2 (en) * 2000-12-08 2003-09-10 Novo Nordisk A/S Tff peptides
EP1383527A4 (en) * 2001-04-24 2004-07-14 Gen Hospital Corp METHOD AND COMPOSITIONS FOR TREATING ORAL AND EYE EYE LESIONS

Also Published As

Publication number Publication date
AU2002351181B2 (en) 2008-08-07
JP2005532988A (ja) 2005-11-04
CN1617739A (zh) 2005-05-18
WO2003045332A3 (en) 2003-07-24
AU2002351181A1 (en) 2003-06-10
MXPA04005053A (es) 2004-09-10
EP1461076A2 (en) 2004-09-29
US20030114384A1 (en) 2003-06-19
EP1461076A4 (en) 2005-03-09
WO2003045332A2 (en) 2003-06-05
US20080167230A1 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
US20080167230A1 (en) Methods and compositions for treating or preventing lesions of the respiratory epithelium
US20090227511A1 (en) Methods and compositions for treating lesions of the respiratory epithelium
US11975005B2 (en) Treatment of respiratory diseases
EP2740487B1 (en) Alpha-i antitrypsin for treating exacerbation episodes of pulmonary diseases
ES3028423T3 (en) Norketotifen for use in the treatment of respiratory disorders
ES2887358T3 (es) Inhibidor de Alfa1-Proteinasa para demorar el comienzo o progresión de exacerbaciones pulmonares
JP5970465B2 (ja) ペプチドおよびウイルス・ノイラミニダーゼ阻害剤を含んでなる組成物
CN102481284A (zh) 穿心莲内酯化合物用于治疗炎症和气道病症的用途
TW201039833A (en) Novel combinations
CN115427576B (zh) 包括透明质酸和蛋白聚糖连接蛋白1的用于预防或治疗肺部疾病的组合物
US20110166149A1 (en) Pteridine derivatives for treating respiratory disease
CN115427569A (zh) 下气道疾病的治疗
US12440488B2 (en) Methods and compositions for treating chronic obstructive pulmonary disease, asthma, pneumonia, bronchitis, cystic fibrosis, pulmonary edema, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, acute respiratory distress syndrome, and pulmonary arterial hypertension
RU2737799C1 (ru) Ингаляционный гексапептид для лечения респираторных заболеваний, связанных с интерлейкином-6
US20060134009A1 (en) Low dose corticosteroid powders for inhalation
US20220339099A1 (en) Compositions of interleukin-1 receptor antagonist
Kearns et al. 88 Levofloxacin pharmacokinetics (PK) after administration of MP-376 (Levofloxacin inhalation solution; Aeroquin) in children with cystic fibrosis (CF)
WO2024077042A2 (en) Il-1 receptor antagonist treatment for neutrophilic lung disease
Janson et al. 4. ACUTE ASTHMA AND COPD EXACERBATIONS
Ito et al. 90 Inhibitory effects of RV1088, a novel narrow spectrum kinase inhibitor, on RSV infection in primary bronchial epithelial cells obtained from patients with cystic fibrosis
Ito et al. 89 Superior effects of RV568, a narrow spectrum kinase inhibitor, on RSV infection in primary bronchial epithelial cells obtained from patients with cystic fibrosis
Keller et al. 91 Medical rationale for nebulisation of a novel high-concentration (100mg/mL) aqueous azithromycin inhalation solution

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued